Keros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare Conference

Core Insights - Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting disorders linked to dysfunctional signaling of the TGF-ß protein family [3] Company Overview - Keros Therapeutics is recognized for its expertise in the TGF-ß protein family, which regulates the growth, repair, and maintenance of various tissues, including blood, bone, skeletal muscle, adipose, and heart tissue [3] - The company is developing several product candidates, including: - Cibotercept (KER-012) for pulmonary arterial hypertension and cardiovascular disorders [3] - KER-065 for neuromuscular diseases [3] - Elritercept (KER-050) for treating low blood cell counts, such as anemia and thrombocytopenia, particularly in patients with myelodysplastic syndrome and myelofibrosis [3] Upcoming Events - Keros' Chair and CEO, Jasbir S. Seehra, Ph.D., will participate in a fireside chat at the Bank of America 2025 Global Healthcare Conference on May 13, 2025, at 8:00 p.m. Eastern time [1] - A live audio webcast of the presentation will be available, with an archived replay accessible for up to 90 days [2]